{"id":"https://openalex.org/W4379280930","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113","title":"LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.","display_name":"LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379280930","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.e21113","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064654222","display_name":"Robert J. Seager","orcid":"https://orcid.org/0000-0002-2866-5288","observed_orcids":["https://orcid.org/0000-0002-2866-5288"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Seager","raw_affiliation_strings":["Omniseq (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Omniseq (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089909718","display_name":"Maria-Fernanda Senosain","orcid":"https://orcid.org/0000-0002-3933-7167","observed_orcids":["https://orcid.org/0000-0002-3933-7167"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria-Fernanda Senosain","raw_affiliation_strings":["OmniSeq Inc. (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq Inc. (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043201399","display_name":"Erik Van Roey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik Van Roey","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shuang Gao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuang Gao","raw_affiliation_strings":["OmniSeq Inc. (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq Inc. (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028036101","display_name":"Paul DePietro","orcid":"https://orcid.org/0000-0001-9072-0631","observed_orcids":["https://orcid.org/0000-0001-9072-0631"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul DePietro","raw_affiliation_strings":["OmniSeq Inc. (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq Inc. (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071349192","display_name":"Mary Nesline","orcid":"https://orcid.org/0000-0003-0523-4597","observed_orcids":["https://orcid.org/0000-0003-0523-4597"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary K Nesline","raw_affiliation_strings":["OmniSeq (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084132159","display_name":"Durga Prasad Dash","orcid":"https://orcid.org/0000-0002-1090-5191","observed_orcids":["https://orcid.org/0000-0002-1090-5191"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Durga P. Dash","raw_affiliation_strings":["OmniSeq Inc. (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq Inc. (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027499943","display_name":"Jeffrey M. Conroy","orcid":"https://orcid.org/0000-0003-1764-9706","observed_orcids":["https://orcid.org/0000-0003-1764-9706"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey M. Conroy","raw_affiliation_strings":["OmniSeq Inc. (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq Inc. (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075920014","display_name":"Heidi Chwan Ko","orcid":"https://orcid.org/0000-0002-7247-9175","observed_orcids":["https://orcid.org/0000-0002-7247-9175"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heidi Chwan Ko","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110312787","display_name":"Stephanie M. Hastings","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Hastings","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077702152","display_name":"Kyle C. Strickland","orcid":"https://orcid.org/0000-0003-1636-5277","observed_orcids":["https://orcid.org/0000-0003-1636-5277"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyle C Strickland","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067892203","display_name":"Rebecca A. Previs","orcid":"https://orcid.org/0000-0001-8087-9120","observed_orcids":["https://orcid.org/0000-0001-8087-9120"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca A. Previs","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026556414","display_name":"Eric Allan Severson","orcid":"https://orcid.org/0000-0003-4394-2412","observed_orcids":["https://orcid.org/0000-0003-4394-2412"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric A Severson","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003764522","display_name":"Taylor J. Jensen","orcid":"https://orcid.org/0000-0002-7206-7656","observed_orcids":["https://orcid.org/0000-0002-7206-7656"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taylor J. Jensen","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016430846","display_name":"Prasanth Reddy","orcid":"https://orcid.org/0000-0002-0350-0110","observed_orcids":["https://orcid.org/0000-0002-0350-0110"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prasanth Reddy","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022385078","display_name":"Shakti H Ramkissoon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shakti Ramkissoon","raw_affiliation_strings":["Labcorp Oncology, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Labcorp Oncology, Durham, NC","institution_ids":["https://openalex.org/I2801558778"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067217729","display_name":"Sarabjot Pabla","orcid":"https://orcid.org/0000-0002-7746-9144","observed_orcids":["https://orcid.org/0000-0002-7746-9144"]},"institutions":[{"id":"https://openalex.org/I2801558778","display_name":"LabCorp (United States)","ror":"https://ror.org/03zsdhz84","country_code":"US","type":"company","lineage":["https://openalex.org/I2801558778"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarabjot Pabla","raw_affiliation_strings":["OmniSeq (Labcorp), Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OmniSeq (Labcorp), Buffalo, NY","institution_ids":["https://openalex.org/I2801558778"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2801558778"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"e21113","last_page":"e21113"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lag-3","display_name":"LAG-3","score":0.9850000143051147},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9490000009536743},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8970000147819519},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.984000027179718},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.6679999828338623},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.953000009059906},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.8220000267028809},{"id":"https://openalex.org/keywords/tim-3","display_name":"TIM-3","score":0.9789999723434448},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.6830000281333923},{"id":"https://openalex.org/keywords/tumor-inflammation","display_name":"tumor inflammation","score":0.4129999876022339},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.8870000243186951},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6759999990463257},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9169999957084656},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.953000009059906},{"id":"https://openalex.org/keywords/gynecologic-cancer","display_name":"gynecologic cancer","score":0.640999972820282},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8001072406768799},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6184629797935486},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6054979562759399},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5694220066070557},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5351873636245728},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4964058995246887},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.45645448565483093},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.43694862723350525},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40057554841041565},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3523961305618286},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.23765802383422852}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.e21113","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.e21113","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.7799999713897705}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2569464488","https://openalex.org/W4414278230","https://openalex.org/W3124354548","https://openalex.org/W3008654489","https://openalex.org/W4200349683","https://openalex.org/W3181358348","https://openalex.org/W2534948582","https://openalex.org/W2772407520","https://openalex.org/W3202518478","https://openalex.org/W2942744719"],"abstract_inverted_index":{"e21113":[0],"Background:":[1],"The":[2],"clinical":[3,438],"utility":[4],"of":[5,66,85,89,127,155,196,236,281,295,389,396],"immune":[6,96],"checkpoint":[7],"inhibitor":[8,33],"(ICI)":[9],"has":[10],"been":[11],"well":[12],"established":[13],"for":[14,34,170,309,417,444],"CTLA-4":[15],"and":[16,60,63,113,118,123,176,220,267,285,301,312,334,413,441],"PD-1/PD-L1":[17],"axis.":[18],"A":[19,81,194],"new":[20],"ICI":[21,58,139,245,371,431],"targeting":[22],"LAG3":[23,48,67,99,203,206,225,239,286,302,310,317,346,359,375,390,407,427],"expressing":[24],"T-cells":[25],"was":[26,92,104,141,166,208,226,240,276,297],"recently":[27],"approved":[28],"in":[29,40,50,69,172,182,198,211,291,320,403,437],"combination":[30,445],"with":[31,37,55,71,78,120,137,147,161,228,243,399,411,419,422,429],"PD-1":[32,249,299],"advanced":[35],"melanoma,":[36],"studies":[38],"underway":[39],"other":[41,56,138,244,430],"cancers.":[42,405],"In":[43,150],"this":[44],"study,":[45],"we":[46],"assess":[47],"expression":[49,68,204,287,391],"a":[51,151,385,393],"pan-cancer":[52,394],"cohort,":[53],"co-expression":[54,428],"known":[57],"targets,":[59],"the":[61,199,292,345],"survival":[62,174,179],"response":[64,184,372],"implications":[65],"patients":[70,159,197,319,348,418],"non-small":[72],"cell":[73],"lung":[74],"cancer":[75],"(NSCLC)":[76],"treated":[77,160,421],"pembrolizumab.":[79],"Methods:":[80],"discovery":[82],"cohort":[83,153,395],"(DC)":[84],"15,630":[86],"FFPE":[87],"tumors":[88],"35":[90],"histologies":[91],"evaluated":[93],"by":[94,102,278,283],"comprehensive":[95],"profiling":[97],"(CIP).":[98],"expression,":[100],"measured":[101],"RNA-seq,":[103],"labeled":[105],"as":[106,132,215,248],"high":[107,207,229,300,303,311,314,318,360],"(rank":[108,111,115],"\u226575),":[109],"moderate":[110,202],"25-74),":[112],"low":[114,347,376],"<":[116,233,253,259,265,272,342],"25),":[117],"compared":[119,344,373],"tumor":[121,237],"inflammation":[122],"cellular":[124,128,230],"proliferation":[125,129,231,412],"(expression":[126],"markers":[130],"such":[131,214,247],"ki-67)":[133],"phenotypes.":[134],"Co-expression":[135],"analysis":[136,165],"targets":[140,246,432],"performed":[142,167],"using":[143,189],"Spearman":[144],"correlation":[145],"(rs)":[146],"p-values":[148],"reported.":[149],"retrospective":[152],"(RC)":[154],"72":[156],"metastatic":[157],"NSCLC":[158],"pembrolizumab":[162,423],"alone,":[163],"Kaplan-Meier":[164],"to":[168,374],"test":[169],"differences":[171],"overall":[173],"(OS)":[175],"progression":[177],"free":[178],"(PFS).":[180],"Differences":[181],"objective":[183],"rate":[185],"(ORR)":[186],"were":[187,307],"determined":[188],"chi":[190],"squared":[191],"test.":[192],"Results:":[193],"majority":[195],"DC":[200,296],"had":[201,362],"(46.63%).":[205],"most":[209],"predominant":[210],"gynecological":[212,404],"cancers":[213,222],"uterine":[216],"(42%),":[217],"ovarian":[218],"(39%)":[219],"cervical":[221],"(37%).":[223],"High":[224],"associated":[227,410],"(p":[232,288],"0.0001),":[234],"regardless":[235],"inflammation.":[238],"significantly":[241,323,363,414],"co-expressed":[242],"(rs>":[250,256,262,269],"0.6,":[251,263],"p":[252,258,264,271,331,341,367],"0.05),":[254,260],"PD-L1":[255,282,313],"0.4,":[257],"PD-L2":[261],"0.05)":[266],"TIM3":[268],"0.5,":[270],"0.05).":[273],"This":[274],"finding":[275],"supported":[277],"significant":[279,426],"association":[280],"immunohistochemistry":[284],"=":[289,328,332,338,351,356,365,368,379],"0.002)":[290],"RC.":[293],"15%":[294],"both":[298],"(2344/15,630).":[304],"Similar":[305],"results":[306],"observed":[308,402],"(1870/15,630;":[315],"12%).":[316],"RC":[321],"showed":[322,384],"higher":[324],"OS":[325,327,350],"(median":[326,336,349],"not":[329,339],"reached;":[330,340],"0.016)":[333],"PFS":[335,337,355],"0.0001)":[343],"12":[352],"months;":[353],"median":[354],"6.5":[357],"months).":[358],"cases":[361,377],"(ORR":[364,378],"65%,":[366],"0.005)":[369],"improved":[370,415],"35%).":[380],"Conclusions:":[381],"Our":[382],"study":[383],"wide":[386],"dynamic":[387],"range":[388],"across":[392],"solid":[397],"tumors,":[398],"highest":[400],"prevalence":[401],"Additionally,":[406],"is":[408],"strongly":[409],"outcomes":[416],"NSCLC,":[420],"alone.":[424],"Furthermore,":[425],"suggests":[433],"its":[434],"plausible":[435],"use":[436],"trial":[439],"selection":[440],"patient":[442],"stratification":[443],"immunotherapy":[446],"strategies.":[447]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2023-06-05T00:00:00"}